obesity
Hims & Hers Won’t Sell Compound Version of Novo’s Obesity Pill
Hims & Hers announced Saturday that it would stop selling what it claims is a cheaper, compounded version of Novo Nordisk’s obesity pill on its telehealth platform, after health officials called for an investigation into the company for potential violations of federal law. Hims launched the compounded drug earlier this week at $49 per month. […]
Roche moves obesity drug into pivotal trials after mid-stage success
Andrew Joseph covers health, medicine and the biopharmaceutical industry in Europe. You can reach Andrew on Signal at drawqjoseph.71. Roche plans to launch Phase 3 studies of its lead obesity candidate this quarter after reporting Tuesday that the drug led to significant weight loss in a mid-stage trial. The drug, known as CT-388, caused an […]
Pfizer wins over Novo to acquire obesity start-up Metsera
Pfizer won the bidding war against Novo Nordisk to acquire Metsera, a biotech specializing in obesity drugs. The pharmaceutical giant increased its offer, valuing the startup at around $10 billion, Metsera announced Friday. In a statement, the biotech also said it received a call from the Federal Trade Commission regarding the potential risks of Novo’s […]
The obesity drug of Novo Nordisk Wegovy is eliminated to treat the puree of living diseases
On Friday, the NOVO Nordisk obesity medication was eliminated on Friday by American regulators to treat an increasingly common liver disease, adding to the list of the conditions for which the therapy with superproduction is now approved. Food and Drug Administration has granted accelerated approval to Wegovy for patients with steatohepatitis associated with metabolic dysfunction, […]